PromarkerD test kit production deal signed

Medtech company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) today reached a strategic milestone in its commercialisation pathway for PromarkerD, the company's predictive test for diabetic kidney disease.

- PILL signs production contract with Monash Antibody Technologies Facility
- Custom antibodies will be designed to recognise the diabetic kidney disease 'fingerprints'
- Strategic milestone in production of a pathology lab test

The company has signed a contract with the Monash Antibody Technologies Facility to produce the custom antibodies needed for a multiplex ELISA (Enzyme-linked immunosorbent assay), which is the precursor to a pathology lab In vitro Diagnostic (IVD) test.

The deal represents the culmination of a detailed evaluation of global manufacturing options and the required make-up of the kit's components.

This follows the successful manufacture of synthetic analogues of the biomarkers that make up the protein 'fingerprints' used to diagnose disease.

The antibodies will be designed to recognise these fingerprints and thereby provide the basis for a sensitive pathology lab assay.

PILL managing director Dr Richard Lipscombe said “We believe the best path to market for the predictive test is as an additional item on the menu of existing pathology lab IVD platforms. Progressing our own go-to-market option gives significant additional bargaining power in the negotiations with global IVD companies.”

In undertaking its own development pathway for PromarkerD as an IVD test kit, in conjunction with ongoing partnering and licensing discussions, PILL now has multiple, complementary commercialisation pathways for PromarkerD as a Laboratory Developed Test (LDT), standard clinical pathology IVD test and Companion Diagnostic (CDx).

The company has recently signed its first million dollar (NPV) licensing deal for the IVD test in the Dominican Republic and the US Territory of Puerto Rico, and continues to work with Newsummit Biopharma Co to commercialise PromarkerD in China.

Background

PILL’s biomarker discovery platform Promarker is being used to target a range of diseases including Alzheimer's, endometrosis and gastro-causing parasites. In each case, once the target fingerprints are identified, the same custom antibody technology can be used to develop a test that can be performed in any pathology lab.

ENDS
About Proteomics International Laboratories (PILL)

PILL (ASX: PIQ) is a medical technology company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Thus proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. **Diagnostics**: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease. By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion.

2. **Analytical services**: Specialist contract research fee-for-service model – focus on biosimilars QC. The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.

3. **Drug discovery**: Therapeutic peptide drug discovery - focus on painkillers and antibiotics. The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase at over 10% per year during 2016-2025.

In combination these areas offer, respectively, medium term products, near term cash flow, and blue sky potential by harnessing one complementary workflow centred on proteins.

About Monash Antibody Technologies Facility

Founded in 2008, the Monash Antibody Technologies Facility (MATF) has become one of the most sophisticated, high-throughput monoclonal antibody facilities in the world. The start-up of MATF was funded by a collaboration between Monash University, the Victorian State Government (The Department of Innovation, Industry and Regional Development) and the Australian Federal Government (Bioplatforms Australia). In June 2015 MATF’s quality management system was ISO9001 certified.